What type of vaccine is nimenrix?

Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. In New Zealand, Nimenrix is only available as a purchased vaccine for individuals from 6 weeks of age through your family doctor.

Is nimenrix the same as Menactra?

Nimenrix and Menveo provide a slightly better immune response compared with Menactra, and a slower decline in protection over time. However, if Menveo and Nimenrix are unavailable, Menactra should be given as it also provides effective protection.

What is nimenrix?

Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

Who makes nimenrix vaccine?

Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline. Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.

Is nimenrix funded?

Menactra® Quadrivalent diphtheria toxoid conjugate 9 month- 55 years Nimenrix® is NIP funded for a single dose at age 12 months, and 14-19 years from April 2019.

What ingredients are in the MenACWY vaccine?

Meningococcal Conjugate or MenACWY Vaccines Each dose contains 4 micrograms (µg) each of meningococcal A, C, W, and Y polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier. It does not contain a preservative or an adjuvant. The manufacturer supplies it as a liquid in a single-dose vial.

Is nimenrix safe?

Nimenrix is well tolerated and the CHMP considered that it can be safely given together with other routinely used vaccines in the different age groups. Therefore, the CHMP decided that the benefits of Nimenrix are greater than its risks and recommended that it be granted marketing authorisation.

What is the difference between nimenrix and Menveo?

In children over 2 years of age, Nimenrix has no advantages over Menveo for vaccination against meningococcal serogroups A, C, W135 andY. In contrast, between the ages of 1 and 2 years, Nimenrix is the only vaccine with established immunogenicity. In addition, it has an acceptable harm-benefit balance.

When should nimenrix be given?

Your baby will receive one dose given from 6 months of age. A booster dose is recommended at 12 months of age, with an interval of at least 2 months after the initial dose. Children from 12 months of age and adults: Most people will be given one NIMENRIX injection.

Is nimenrix FDA approved?

Based on clinical evidence, Nimenrix was approved for administration in infants as a two dose primary series, with the first dose given from six weeks of age and with an interval of two months between doses, followed by a booster dose at 12 months. The six confirmatory co-primary objectives of the study were met.

Is nimenrix approved in the US?

Many American universities require students to be vaccinated against meningococcal disease (type ACWY). In Europe, there are two approved vaccines, Menveo and Nimenrix, of which only Menveo is approved in the USA.

Is meningococcal vaccine free in Australia?

In Australia, a free meningococcal ACWY vaccine is provided for children at 12 months of age and in Year 10 of secondary school (or aged 15 to 19 years).